Mesenchymal stromal cell-derived small extracellular vesicles modulate macrophage polarization and enhance angio-osteogenesis to promote bone healing

Mesenchymal stem/stromal cells (MSCs) have demonstrated therapeutic efficacy for bone regeneration in animal and clinical studies. Although MSCs were initially thought to differentiate to various cell types to replace the injured/diseased tissue, it is now accepted that these cells secrete factors to promote tissue repair. Among these factors, small extracellular vesicles (sEVs) of size 50–200 nm, which include the exosomes, have been identified as the principal agent mediating the wide-ranging therapeutic efficacy of MSCs. Several studies have also reported the therapeutic effects of MSC-sEVs to enhance bone repair in animal models, as recently reviewed. However, the cellular processes and mechanisms mediated by MSC-sEVs in bone regeneration remain to be fully elucidated.

In this study, we employed a rat calvaria defect model to investigate the cellular processes activated by MSC-sEVs during bone repair (Supplementary Methods). Briefly, MSC-sEVs were prepared as previously described, and characterized in accordance with the MISEV2018 guidelines. Collagen sponges with 100 μg MSC-sEVs in 100 μl PBS (CS/sEVs) or equivalent volume of phosphate-buffered saline (PBS, CS/Control) were implanted to 8-mm diameter critical-size calvaria defects surgically created in 32 rats. Another five rats served as age-matched naive control. At 1 and 8 weeks, samples were harvested for analyses using micro-computed tomography (micro-CT), histology and immunohistochemistry.

Micro-CT analysis revealed minimal bone formation in both groups at 1 week (Fig. S1). Despite limited bone formation, CS/sEVs group showed better cell infiltration and matrix deposition than the CS/Control group (Fig. 1A). Differences were more evident at 8 weeks, with CS/sEVs group showing new bone that completely bridged the defect, as opposed to CS/Control group having limited new bone, mostly confined to the defect periphery (Fig. 1A). Notably, CS/sEVs displayed significantly higher BV/TV, Tb.Th and Tb.N, but lower Tb.Sp than the CS/Control group and was comparable to that of the naive control (Fig. S1). Consequently, CS/sEVs group had an overall micro-CT score of 3.9 ± 0.2 that was significantly higher than CS/Control group with 2.5 ± 0.8 and was comparable to that of the naive control with 4 ± 0.0 (Fig. S1). At 8 weeks, CS/sEVs group displayed histological improvements in new bone formation, marrow changes and bone cortex remodelling that culminated in a significantly better score of 5.4 ± 1.0 over the CS/Control group with 2.6 ± 1.8 (Fig. 1B). Compared to the naive control, the defect repair in CS/sEVs group was near completion as evidenced by a slightly lower but statistically not different scores in the histological parameters measured.

Further analyses by immunohistochemistry revealed significantly higher percentage areal deposition of osteocalcin (OCN) in the CS/sEVs group than the CS/Control group, that persisted to 8 weeks (Fig. 1C). By 8 weeks, CS/sEVs group had ~2.5-fold higher areal deposition of OCN than CS/Control group (Fig. 1C). On the other hand, CS/sEVs group had ~2-fold higher number of CD31⁺ microvessels than CS/Control group at 1 week (Fig. 1D). However, the number of CD31⁺ microvessels declined at 8 weeks in both groups with no significant difference (Fig. 1D). Additionally, CS/sEVs group showed a significantly higher number of PCNA⁺ proliferative cells than the CS/Control group at 1 week. The number of PCNA⁺ cells declined at 8 weeks in both groups with no...
Figure 1  MSC-sEVs promote bone regeneration through increased angiogenesis and osteogenesis, and enhanced M2 over M1 macrophage infiltration. (A) Histological and histomorphometric analyses of calvarial bone regeneration at 1 and 8 weeks by hematoxylin and eosin (HE) staining and modified histological scoring (B) that assessed parameters including new bone formation, marrow changes and cortex remodeling. Data are presented as mean ± SD (n = 8), *P < 0.05, **P < 0.01 compared to CS/Control. ##P < 0.01, ###P < 0.001 compared to naive control group. Immunohistochemical staining and quantitative analysis of OCN stained
significant difference (Fig. 52A). Conversely, the number of CCP3+ apoptotic cells were similar in both CS/sEVs and CS/Control groups at 1 week but declined at 8 weeks in both groups (Fig. 52B). As immune response is integral to tissue repair upon injury, we examined if there was a difference in macrophage infiltration into the defect site during bone regeneration. As early as 1 week, we observed an abundance of CD206+ M2 macrophages, with CS/sEVs group having a significantly higher number of CD206+ cells than the CS/Control group (Fig. 1E). Thereafter, the number of CD206+ cells declined in both groups with no significant difference (Fig. 1F).

In contrast to M2 macrophages, the number of CD86+ M1 macrophages in the CS/sEVs group was significantly lower than that in CS/Control group at 1 week (Fig. 1F). By 8 weeks, the number of CD86+ cells declined in both groups with no significant difference (Fig. 1F). These observations were further supported by the evaluation of M1 macrophage-associated pro-inflammatory cytokines, namely IL-1β and TNF-α. At 1 week, CS/sEVs group relative to CS/Control group had significantly lower numbers of IL-1β+ and TNF-α+ cells. At 8 weeks, the number of IL-1β+ and TNF-α+ cells declined in both groups with no statistically significant difference (Fig. 53A, B). Collectively, our findings demonstrated that MSC-sEV-mediated bone healing is largely characterized by increased cellular proliferation and infiltration, improved vascularization, and mineralization, and enhanced M2 over M1 macrophage infiltration with reduced inflammation.

To gain insights into the cellular processes activated by MSC-sEVs during bone repair, cell culture studies utilizing MSCs, endothelial cells and macrophages were performed (Supplemental Methods). Consistent with our animal results that observed enhanced new bone formation, we found that MSC-sEVs significantly enhanced osteogenic differentiation of MSCs in a dose-dependent manner with 10 μg/ml MSC-sEVs demonstrating the highest levels of eluted dye and calcium deposition (Fig. 1G, H). This enhancement in osteogenic differentiation by MSC-sEVs was also supported by our gene expression analysis showing upregulation of osteogenic genes such as OCN, BMP-2, RUNX2, OSX, ALP and OPN (Fig. 1I). Similarly, we observed that MSC-sEVs enhanced endothelial cell migration, proliferation, and tube formation in a dose-dependent manner, with 10 μg/ml MSC-sEVs having the most potent effects (Fig. 1J–N). Our gene expression analysis also showed that MSC-sEVs elevated several angiogenic genes including VEGF-A, PDGF-C, TGF-β1, CD31, VEGFR2 and ANGPT1 (Fig. 1O). These findings suggest that the enhanced vascularization and mineralization observed during bone repair in our animal model could be attributed to MSC-sEV-enhanced angiogenesis and osteogenesis.

Next, we tested the effects of MSC-sEVs on macrophage polarization. naive M0 macrophages were treated with LPS and IFN-γ (M1) or IL-4 (M2) to polarize to M1 or M2 macrophages, respectively. We found that MSC-sEVs suppressed the expression of M1 macrophage markers, iNOS and TNF-α, and the associated genes including CD80, IFN-γ, TNF-α, IL-1β, IL-12β and iNOS in LPS+IFN-γ+sEVs group, compared to LPS+IFN-γ group (Fig. 1P, Q). On the contrary to the suppressive effects of MSC-sEVs on (LPS+IFN-γ)-mediated M1 polarization, MSC-sEVs treatment was able to enhance (IL-4)-mediated M2 polarization as evidenced by the increased expression of M2 macrophage markers, CD206 and Arg1, and associated genes, including CD206, Retnla, SOCS1, Arg1 and TGF-β1 (Fig. 1R, S). Despite having effects on M1 or M2 polarized macrophages, MSC-sEVs had little effects on the expression of M1 or M2 macrophage-associated markers by the naive macrophages (Fig. 1P–S). These results suggest that the preferential M2 over M1 macrophage infiltration observed during bone repair in our animal model could be attributed to the enhanced M2 over M1 macrophage polarization mediated by MSC-sEVs.

In summary, we observed that MSC-sEV-mediated bone healing was characterized by increased cellular proliferation and infiltration, enhanced vascularization and mineralization, and reduced inflammation with a regenerative macrophage phenotype. By means of cell areas (C) and CD31+ microvessels (D). Data are presented as mean ± SD (n = 8). *P < 0.05, **P < 0.01 compared to CS/Control. Immunohistochemical staining and quantitative analysis of CD206 (E) and CD86+ cells (F). Data are presented as mean ± SD. *P < 0.05, **P < 0.01 compared to CS/Control. MSC-sEVs enhanced osteogenic differentiation of MSCs (G–I). MSCs were cultured in osteogenic medium (OM) supplemented with 1, 5 and 10 μg/ml of sEVs or vehicle (PBS) for 21 days. MSCs cultured in growth medium (GM) served as a control. (G) Alizarin red S staining with quantification of eluted dye and calcium deposition by (H) showed dose-dependent effect of MSC-sEV on osteogenic differentiation of MSCs. (I) RT-qPCR analysis showed upregulation of genes associated with osteogenesis (OCN, BMP-2, RUNX2, OSX, ALP, OPN). Data are presented as mean ± SD (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001 compared to growth medium control. P < 0.05, **P < 0.01, ***P < 0.001 compared to OM+PBS group. MSC-sEVs also promoted migration, proliferation and tube formation of endothelial cells (EA.hy926) (J–Q). (J) Transwell migration assay showed dose-dependent effect of MSC-sEVs on endothelial cell migration. (K) MTS cell metabolic activity assay and DNA assay (L) showed potent dose and time-dependent effects of MSC-sEVs on endothelial cell metabolic activity and proliferation. Tube formation assay measuring the number of tubes (M) and total tube area (N) showed dose-dependent effects of MSC-sEVs on angiogenesis. (O) RT-qPCR analysis showed upregulation of genes associated with angiogenesis (VEGF-A, PDGF-C, TGF-β1, CD31, VEGFR2 and ANGPT1). Data are presented as mean ± SD (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001 compared to control. MSC-sEVs enhanced M2 over M1 polarization of rat alveolar macrophages (NR8383) (P–S). (P) Western blot analysis of iNOS, TNF-α and GAPDH. (Q) RT-qPCR analysis of genes associated with M1 macrophages (CD80, IFN-γ, TNF-α, IL-1β, IL-12β, and iNOS). (R) Western blot analysis of CD206, Arg1 and GAPDH. (S) RT-qPCR analysis of genes associated with M2 macrophages (CD206, Retnla, CD204, SOCS1, Arg1 and TGF-β1). Data are presented as mean ± SD (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001 compared to control group.
culture studies, we could attribute some of the cellular activities mediated by MSC-sEVs during bone repair to increased osteogenic mineralization of MSCs, enhanced migration and tube formation of endothelial cells, as well as anti-inflammatory M2 over pro-inflammatory M1 polarization of the macrophages.

**Author contributions**

Investigation, formal analysis, data curation, visualisation and writing — original draft: SJC, CWY, KYWT, JRJC, YAC, SZ. Writing — reviewing and editing: RCWW, AATL. SKL: Funding acquisition, writing — reviewing and editing. WST: Conceptualization, methodology, validation, data curation, supervision, funding acquisition, writing — reviewing and editing.

**Conflict of interests**

SKL holds founder shares in Paracrine Therapeutics Pte Ltd. All other authors have no commercial, proprietary or financial interest in the products or companies described in this article.

**Funding**

This work was funded by National University of Singapore (No. R221000114114, R221000134114) and National Medical Research Council Singapore (No. R221000123213). SKL and WST are supported by the Agency for Science, Technology and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-Positioning (No. H19H6a0026).

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.gendis.2021.11.012.

**References**

1. Meirelles Lda S, Fontes AM, Covas DT, Caplan Al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20(5–6):419–427.

2. Witwer KW, Van Balkom BW, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019;8(1):1609206.

3. Tan SHS, Wong JRY, Sim SJY, et al. Mesenchymal stem cell exosomes in bone regenerative strategies—a systematic review of preclinical studies. Mater Today Bio. 2020;7:100067.

4. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4(3):214–222.

5. Théry C, Witwer KW, Akawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.